Alex joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial and operational experience in the biotechnology industry to her role.
Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she was responsible for strategic planning, finance and accounting. During her time at SQZ Biotechnologies, she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Before joining SQZ, Alex served as Corporate Controller at Agios Pharmaceuticals, where she built the finance and accounting teams and contributed to the company’s strategic financing efforts, raising more than $700 million in equity financing, including playing a key role in the 2013 initial public offering. Alex was responsible for all financial functions of the company including strategic planning, treasury, tax, finance and accounting. Earlier in her career, Alex held positions at both Molecular Insight Pharmaceuticals, a publicly-traded oncology company, acquired in 2013 and Coley Pharmaceuticals, a publicly-traded company developing immunotherapies for cancer and other disease areas, acquired by Pfizer in 2007.
Alex earned her B.B.A in finance from the University of Massachusetts, Amherst and her M.B.A from Boston College. Alex is also a certified public accountant in Massachusetts.
What is Alexandra Balcom's net worth?
The estimated net worth of Alexandra Balcom is at least $2.80 million as of October 31st, 2024. Ms. Balcom owns 33,300 shares of Nuvalent stock worth more than $2,804,526 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Balcom may own. Additionally, Ms. Balcom receives an annual salary of $689,410.00 as CFO at Nuvalent. Learn More about Alexandra Balcom's net worth.
How old is Alexandra Balcom?
Ms. Balcom is currently 39 years old. There are 5 older executives and no younger executives at Nuvalent. The oldest executive at Nuvalent is Prof. Matthew D. Shair Ph.D., Founder, Head of Scientific Advisory Board & Director, who is 55 years old. Learn More on Alexandra Balcom's age.
What is Alexandra Balcom's salary?
As the CFO of Nuvalent, Inc., Ms. Balcom earns $689,410.00 per year. There are 2 executives that earn more than Ms. Balcom. The highest earning executive at Nuvalent is Dr. James R. Porter Ph.D., CEO, President & Director, who commands a salary of $1,050,000.00 per year. Learn More on Alexandra Balcom's salary.
How do I contact Alexandra Balcom?
Has Alexandra Balcom been buying or selling shares of Nuvalent?
In the last ninety days, Alexandra Balcom has sold $891,900.00 in shares of Nuvalent stock. Most recently, Alexandra Balcom sold 10,000 shares of the business's stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $89.19, for a transaction totalling $891,900.00. Following the completion of the sale, the chief financial officer now directly owns 33,300 shares of the company's stock, valued at $2,970,027. Learn More on Alexandra Balcom's trading history.
Who are Nuvalent's active insiders?
Are insiders buying or selling shares of Nuvalent?
During the last year, insiders at the sold shares 43 times. They sold a total of 3,520,279 shares worth more than $309,132,982.40. The most recent insider tranaction occured on December, 16th when CEO James Richard Porter sold 27,000 shares worth more than $2,338,470.00. Insiders at Nuvalent own 12.5% of the company.
Learn More about insider trades at Nuvalent. Information on this page was last updated on 12/16/2024.
